Company: BIVIW
Filing Date: 2025-08-08
Form Type: 424B5
Source: 0001520138-25-000247
Chunk: 110

Company: BIOVIE INC.
Filing Date: 2025-08-08
Form: 424B5
Chunk 110
---
 17 years
and helped build the healthcare, high tech and corporate finance practices. He holds a BA from Dartmouth College, and an MBA from the
Tuck School of Business at Dartmouth.

We believe Mr. Do’s qualifications to serve
on our Board of Directors and as the CEO and President are primarily based on his decades of experience as an executive in the pharma,
biotech, and other high technology industries and his extensive experience in strategy, corporate finance practice and the development
of companies in all stages.

Ms. Joanne Wendy Kim has served as the
Company’s Chief Financial Officer since 2018. Ms. Kim previously served as Chief Financial Officer (“CFO”) for several
companies throughout her career, previously with Landmark Education Enterprises, and prior to that, other public entities in the entertainment
and financial services industry sectors. She provided interim CFO services to various organizations through Group JWK from 2016 to 2018.
In her various roles, Ms. Kim oversaw corporate finance and operational groups, closed eight acquisitions, secured bank financings, developed
and implemented new business strategies, managed risk and implemented new financial policies and procedures. As a CPA professional, she
advised on accounting transactions, SEC reporting matters and other regulatory matters to clients serving as a Director at BDO USA, LLP’s
National Office SEC Department and sat the US desk in London for BDO LLP UK Firm in 2008-2016 and as a Senior Manager at KPMG in earlier
part of her career. She brings more than 35 years of accounting and finance experience to this position. Ms. Kim earned her BSA in accounting
and finance at California State University, Long Beach.

Ms. Kim’s qualifications to serve as our
Chief Financial Officer are primarily based on her 35 years of accounting and finance experience both as a CFO and as a CPA in major
global accounting and consultancy firms.

Dr. Joseph M. Palumbo has served as our
Chief Medical Officer (“CMO”) since 2021. Formerly he served as the CMO at Zynerba Pharmaceuticals from July 2019 to October
2021, responsible for clinical operations, development, regulatory, and medical affairs. Prior to his time at Zynerba, Dr. Palumbo held
senior worldwide governance roles at Mitsubishi Tanabe Pharma in both the United States and Japan from April 2012 to June 2019, where
he led medical science and translational research across multiple therapeutic areas, and guided